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Abstract Leukopenia is a considerably common complica-
tion of tocilizumab [TCZ] and rituximab [RTX] therapy.
RTX-induced leukopenia typically exhibits delayed onset.
While agranulocytosis has been reported linked to RTX
treatment of lymphoma, this complication rarely occurs in
rheumatoid arthritis (RA) treatment and, to our knowledge,
has never been reported in association with TCZ therapy.
We herein report four agranulocytosis cases in three patients,
with the first two cases suspected to be secondary to human
parvovirus B19 (PVB19) infection. Agranulocytosis
manifested in the first patient 2 months following a third
RTX course. Bone marrow (BM) polymerase chain reaction
(PCR) was positive for PVB19. The patient relapsed after
three TCZ courses, with her PCR again positive for PVB19.
Both episodes resolved under granulocyte-macrophage
colony-stimulating factor (GM-CSF). In the second patient,
agranulocytosis manifested after the 74th TCZ course. Bone
marrow PCR was positive for PVB19, and the evolution was
favorable under intravenous immunoglobulin administration.
The third case was a 53-year-old female patient with
seropositive RAwho presented agranulocytosis after the first
infusion of her fourth RTX course. Unfortunately, no PCR
PVB19 was made on myelogram. Evolution was favorable
after 5 days of GM-CSF. PVB19 infection should be
investigated in patients suffering from agranulocytosis
manifesting during biotherapy. In cases manifesting from the
15th day of RTX treatment onwards, hemogram must be
conducted before readministering the infusion.
Keywords Agranulocytosis . Drug-related side effects and
adverse reactions . Human . Parvovirus B19 . Rheumatoid
arthritis
Introduction
Prognosis of rheumatoid arthritis (RA) has been radically
changed since the introduction of biologic disease-
modifying antirheumatic drug. Among the adverse events of
these treatment, leukopenia is common under tocilizumab
(TCZ) and rituximab (RTX) [1–4]. However, agranulocytosis
defined by neutrophils count <0.5 G/L on hemogram remains
rare. Agranulocytosis has been already reported manifesting
during RTX therapy for lymphoma (as late-onset neutropenia,
LON); yet to our knowledge, this complication is less com-
mon in RA treatment and has never been reported during TCZ
therapy[4–7]. The incidence and etiologies of LON are largely
discussed in literature. The overall incidence, calculated from
series published in hematology, was estimated at 3–27% [6].
In RA, the incidence was estimated at 1.3% of all treated
patients [7], caused by blocked medullary granulocytic matu-
ration occurring 3 to 4 weeks after RTX infusion. The poten-
tial causes found are drug toxicity, antigranulocyte antibody
production, neutrophil apoptosis by the large granular lym-
phocyte population, polymorphisms in the IgG receptor FC
γ RIIIA, SDF 1 synthesis during lymphocyte B recovery, as
well as viral infection [5–9]. Among the viral pathogens, hu-
man parvovirus B19 could be a causative agent (PVB19).
PVB19 infection is known to induce transient aplasia. It can
also cause leukopenia and agranulocytosis in both healthy and
immunocompromised individuals[10–12]. We herein report
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four agranulocytosis episodes in three RA patients undergoing
TCZ or RTX therapy. PVB19 infection was detected in two of
our observed cases and could have accounted for the agranu-
locytosis observed under biotherapy.
Clinical cases
Case 1
This 32-year-old female had a history of cerebellar ataxia and
seronegative RA that started in 2004. Following the failure of
three antitumor necrosis factor alpha (anti-TNFα) agents,
namely adalimumab, infliximab, and etanercept combined
with methotrexate (MTX), RTX was administered in
November 2006. Treatment was recommenced in November
2008 and November 2009. MTX was discontinued in
December 2010 then RTX administered in February 2011.
Two months later, a full blood count (FBC) performed due
to fever revealed isolated agranulocytosis (0.03 G/L)
(hemoglobin (Hb): 12.2 g/dL, platelets: 339 G/L) with severe
inflammatory syndrome (C-reactive protein (CRP): 110 mg/
L). The infection work-up was negative: urine cultures
revealed no growth; pneumococcal and legionella urinary
antigen tests were negative; tests for mycoplasma
pneumoniae, chlamydia pneumoniae, HIV, hepatitis B virus
(HBV), hepatitis C virus (HCV), and cytomegalovirus (CMV)
were negative; Epstein-Barr virus (EBV): IgG positive and
IgM negative; and parvovirus: IgG positive and IgM negative.
The patient’s morphological examinations were normal.
Myelogram revealed precursor block at the promyelocytic
stage. Polymerase chain reaction (PCR) was positive for
PVB19 in the bone marrow (BM) and negative in the blood.
Granulocyte-macrophage colony-stimulating factor
(GM-CSF) treatment was administered for 48 hours.
Leukocytes normalized by day 4. In January 2012, the RA
flared up again, and TCZ therapy was initiated. FBC
performed prior to the fourth treatment course revealed
agranulocytosis (neutrophils: 0 G/L). The clinical examination
was normal. Myelogram demonstrated precursor block in the
promyelocytic stage, and the PCR once again detected
PVB19. The patient’s infection work-up was negative, and
she improved within 72 hours of receiving GM-CSF.
Case 2
This 70-year-old female had a history of recurring pulmonary
embolism and suffered from a seronegative RA, diagnosed in
1969. Firstly, she was treated with aurothiopropanol then
sulfasalazine and MTX with hydroxychloroquine. She was
also given corticosteroids. In 2001, her RA flared up.
Anti-TNFa treatment was initiated, replaced in 2007 by
abatacept until 2009. Due to a new RA episode, TCZ was
started (8 mg/kg) in association with MTX in 2009. There
were no infusion complications. In 2015, 1 month after the
last infusion (75th), neutropenia occurred, with a neutrophil
level of 0.1 G/L declining to 0.08 G/L in 1 week. The patient’s
clinical examination was normal. Other biological tests
disclosed aregenerative anemia (Hb: 9.7 g/dL, reticulocytes:
85.2 G/L), with lymphopenia (0.360 G/L), while platelet
count was normal (247 G/L). Serological tests revealed no
recent viral infection (CMV: IgG+, IgM−; EBV: IgG+, IgM
−; PVB19: IgG+, IgM−). PCR was positive for PVB19 in the
bone marrow: 65 cop/mL (>42) yet negative in the blood. No
vitamin B12 or folate deficiencies were identified, with
normal liver and kidney analyses. There was no inflammation,
and blood cultures were negative. Myelogram revealed
normal abundance of three lineages with a blockade of
neutrophil lineage at the promyelocyte/myelocyte stage,
which indicated agranulocytosis. All treatments (MTX and
TCZ) were stopped. Intravenous immunoglobulins (IgIV)
were infused at 1 mg/kg for 2 days. There were no
complications. Three days post-infusion, the polynuclear
neutrophil (PNN) level increased and remained constant at
1.7 G/L. TCZ was reinitiated 7 days after agranulocytosis at
half the original dosage in association with MTX, resulting in
no further hematological complications.
Case 3
This 53-year-old female displayed no relevant medical his-
tory except for thyroidectomy due to goiter and seroposi-
tive RA diagnosed in 2005. She was initially treated with
MTX then an MTX-adalimumab combination in 2005,
followed by TCZ and etanercept in 2011, each discontinued
in turn due to insufficient efficacy. RTX was introduced in
March 2012 and again in November 2012 and April 2013.
Hydroxychloroquine was added due to persistent RA flare-
up in February 2013. In November 2013, the patient re-
ceived 1 g of RTX. Her FBC, performed prior to the second
infusion, revealed isolated neutropenia (0.089 G/L). The
patient was apyretic despite left maxillary sinusitis, which
was resolving. Myelogram revealed neutrophilic granulo-
cytic hypoplasia with blocked promyelocytic maturation,
along with an absence of mature elements, suggesting
agranulocytosis. Viral serology (HIV, HBV, HCV, EBV,
and PVB19) was negative in the blood. No parvovirus
PCR was performed in the bone marrow. All treatments
were discontinued. The patient’s condition evolved
favorably within 5 days of initiating GM-CSF.
Discussion
We herein report four agranulocytosis episodes manifesting in
three patients under biotherapy, with two of the episodes being
2616 Clin Rheumatol (2016) 35:2615–2618
possibly secondary to PVB19 infection. The first patient’s
PCR was positive for PVB19 when she developed
agranulocytosis while receiving RTX then TCZ. In the second
episode, the PCR was also positive when agranulocytosis
manifested under TCZ.
Neutropenia is a common complication of TCZ and RTX
treatment in RA patients. The LITHE, STREAM, and
AMBITION studies observed 17 (4.3 %), nine (6.2 %), and
nine (3.1 %) cases of stage 3 neutropenia (PNN 0.5–1 G/L),
respectively, in TCZ-treated patients receiving 8 mg/kg [1–3].
Temporarily blocked demargination of the polynuclear neu-
trophils, usually mediated by IL6, appeared responsible, with
no bone marrow abnormalities detected [13]. Agranulocytosis
has never been reported associated with TCZ use in RA.
Under RTX, most cases of neutropenia secondary to infu-
sion are described as late-onset neutropenia (LON), notably in
hematological series [7]. Marotte et al. are the first authors
who reported agranulocytosis in an RA patient manifesting
8 weeks after the first RTX infusion. They detected a blocked
granulocytic maturation on myelogram, with favorable evolu-
tion achieved on initiating GM-CSF. The underlying neutro-
penia mechanism remained unclear, with low residual RTX
concentrations and absence of antigranulocyte antibodies.
Virus was thus suspected, notably PVB19 [5]. The possibility
of RTX, agranulocytosis, and PVB19 association has already
previously been raised in one neutropenia case in a patient
treated for primary biliary cirrhosis [14].
Parvovirus B19 uses the human erythroid progenitor for
natural host cells[11]. Pure red-cell aplasia is the most
common feature, while some other hematological compli-
cations may also occur. Although erythroid progenitors
appear specific permissive cells for PVB19 replication,
neutropenia with agranulocytosis and thrombocytopenia
or pancytopenia has also been reported in the literature
[11, 12, 17]. A primo-infection as well as virus reactivation
can induce neutropenia. In immunocompromised patients,
reactivation of PV B19 detected by PCR can occur at low
levels of parvovirus replication owing to absent antiviral
immunity [16]. Several publications have testified to an
association between neutropenia, agranulocytosis, and
PVB19 in both healthy and immunocompromised patients.
McClain K. et al. and Istomin V. et al. reported 15 PVB19-
positive PCRs in 19 chronic neutropenia children and five
agranulocytosis cases in 23 patients with acute PVB19 in-
fection, respectively [15, 17]. Two pure agranulocytosis
cases, secondary to PVB19 infection, were also reported
by Pont and Herzog-Tzarfati [18, 19]. In immunocompro-
mised cases, comparable to our three cases, Barlow et al.
reported that the majority of the 26 documented cases of
PVB19-related neutropenia occurred in hemopathic or im-
munocompromised patients [20]. In a case of late-onset
neutropenia (LON) under RTX, Hartman et al. described
one patient treated for lymphoma presenting negative
blood tests, with only her blood and bone marrow PCRs
testing positive, and no other abnormalities indicating PV
infection [21]. Her evolution was favorable under IgIV
administration. In addition, Christopeit et al. described
PV infection being responsible for a LON case, with only
the bone marrow PCR positive for PV [22]. This context is
comparable to our first case, where the PV infection could
have been responsible for the agranulocytosis under RTX,
as well as the relapse under TCZ, with the latter inducing
immunodepression via antilymphocyte B activity, thus
explaining the agranulocytosis [23]. Unfortunately, no test
for PV B19 on bone marrow was performed to our third
case. We can only present the occurrence of agranulocyto-
sis 2 weeks after RTX infusion but can not confirm
parvovirus responsibility.
The association between agranulocytosis and PVB19
remains complex, and the viral replication’s exact role in
neutropenia pathogenesis is still unclear [24–26]. PVB19
may either inhibit myeloid cell development or exhibit a direct
cytotoxic effect [25]. Induction of antigranulocyte antibodies
was also considered. In a study on 240 patients with
autoimmune neutropenia, 36 exhibited seroconversion and/
or positive DNA in the blood [27]. Of these 36, 24 were
retested after neutropenia remission and all remained negative
for parvovirus [27]. In our cases, this hypothesis could not
explain the neutropenia. We searched for antigranulocyte an-
tibodies, but all were negative, whereas the PVB19 serology
and DNAwere positive in either the blood or bone marrow.
Lastly, to treat infection or reactivation, at least temporarily
discontinuing immunosuppressive therapy is advised.
Granulocyte-stimulating factors should primarily be used in
cases of general neutropenia that last a few days. In such
resistant or severe cases, intravenous immunoglobulin can
provide antibodies against PVB19 and proves highly effec-
tive. Such a regimen should be administered at either 0.4–
0.5 g/kg per day during 5 to 10 days or 1 g/kg for 2 days
[10, 18]. The PCR should subsequently become negative for
PVB19. Neutropenia relapse may require new immunoglob-
ulin administration [11]. PCR can prove instrumental for mon-
itoring response to immunoglobulin administration and
predicting relapse.
Conclusion
PVB19 presence in the blood and bone marrow should be
investigated in neutropenia patients receiving disease-
modifying antirheumatic drugs. New studies are required in
order to further explore this association. In cases where
agranulocytosis manifests from the 15th day of RTX
treatment, unlike typical LON timing, a hemogram must be
conducted prior to reinitiating the infusion.
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